- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BIO-WORKS TECHNOLOGIES AB: Business Update | 1 | Cision News | ||
| 29.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million | 5 | Cision News | ||
| 15.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News | ||
| 07.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| 06.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News | ||
| 08.10.25 | BIO-WORKS TECHNOLOGIES AB: Strong interest in WorkBeads affimAb Edge: Next-Generation Protein A Resin for Antibody Purification | 3 | Cision News | ||
| 07.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies wins appeal against the Swedish Tax Agency in the Supreme Administrative Court | 2 | Cision News | ||
| 01.10.25 | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the fourth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 20.08.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Launches WorkBeads affimAb Edge: Strategic Expansion in the Protein A Resin Market | 1 | Cision News | ||
| 19.08.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders have informed of their intention to exercise all their Warrants TO2 | 1 | Cision News | ||
| 14.08.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB will be publishing the Q2 interim report 2025 tomorrow Friday the 15'th of August | 2 | Cision News | ||
| 15.07.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 3 of 11 | 1 | Cision News | ||
| 11.07.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company | 1 | Cision News |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 1,300 | -4,41 % | Helix BioPharma Corp.: Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025 | TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where... ► Artikel lesen | |
| GALECTO | 21,630 | -1,64 % | Leerink Partners initiates coverage on Galecto stock with Outperform rating | ||
| JYONG BIOTECH | 4,100 | +11,11 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 23,950 | +49,69 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,755 | +36,87 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ALUMIS | 17,325 | +6,62 % | Should You Chase the Rally in Alumis Stock Today? | ||
| PRAXIS PRECISION MEDICINES | 289,78 | +6,15 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| REGENCELL BIOSCIENCE | 48,000 | +43,67 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| BIONTECH | 85,20 | +1,49 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| EVOTEC | 6,290 | +8,86 % | Evotec, K+S, Puma, Redcare Pharmacy, Renk, Vossloh - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,23 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,830 | +6,15 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| KYMERA THERAPEUTICS | 74,57 | +1,52 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| COGENT BIOSCIENCES | 34,860 | +0,23 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,255 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.